Impaired transcription factor interplay in addition to advanced glycation end products suppress podocalyxin expression in high glucose-treated human podocytes

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 3, 2009, Pages

  Drossopoulou, Garyfalia I ^a   Tsotakos, Nikolaos E ^a   Tsilibary, Effie C ^a  

^a Institute of Biology   (Greece)

Author keywords

Diabetes; Gene regulation; Glomerular epithelial cells; High glucose

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOSE; MESSENGER RNA; PODOCALYXIN; TRANSCRIPTION FACTOR; WT1 PROTEIN;

ARTICLE; CELL IMMORTALIZATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL CULTURE; LONG TERM EXPOSURE; PODOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION;

EID: 69449093150     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00203.2009     Document Type: Article

References (40)

1. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632, 1986. (Pubitemid 16095602)
2. Butta N, Larrucea L, Alonso S, Rodriguez RB, Arias-Salgado EG, Ayuso MS, González-Manchón C, Parrilla R. Role of transcription factor Sp1 and CpG methylation on the regulation of the human podocalyxin gene promoter. BMC Mol Biol 7: 17-29, 2006. (Pubitemid 43950610)
3. Carpenter B, Hill KJ, Charalambous M, Wagner KJ, Lahiri D, James DI, Anderson JS, Schumacher V, Royer-Pokora B, Mann M, Ward A, Roberts SGE. BASP1 is a transcriptional cosuppressor for the Wilms' tumour suppressor protein WT1. Mol Cell Biol 24: 537-549, 2004. (Pubitemid 38057907)
4. Dame C, Sola MC, Lim KC, Leach KM, Fandrey J, Ma Y, Knopfle G, Engel JD, Bungert J. Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem 279: 2955-2961, 2004. (Pubitemid 38114288)
5. Dame C, Kirschner KM, Bartz KV, Wallach T, Hussels CS, Scholz H. Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene. Blood 107: 4282-4290, 2006. (Pubitemid 43801352)
6. Delarue F, Virone A, Hagege J, Lacave R, Peraldi MN, Adida C, Rondeau E, Feunteun J, Sraer JD. Stable cell line of TSV40 immortalized human glomerular visceral epithelial cells. Kidney Int 40: 906-912, 1991.
7. Doyonnas R, Kershaw DB, Duhme C, Merkens H, Chelliah S, Graf T, McNagny KM. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 194: 13-27, 2001. (Pubitemid 32660434)
8. Dutta U, Cohenford MA, Dain JA. Nonenzymatic glycation of DNA nucleosides with reducing sugars. Anal Biochem 345: 171-180, 2005. (Pubitemid 41375948)
9. Eble AS, Thorpe SR, Baynes JW. Non-enzymatic glucosylation and glucose-dependent cross-linking of protein. J Biol Chem 258: 9406-9412, 1983.
10. Economou CG, Kitsiou PV, Tzinia AK, Panagopoulou E, Marinos E, Kershaw DB, Kerjaschki D, Tsilibary EC. Enhanced podocalyxin expression alters the structure of podocyte basal surface. J Cell Sci 117: 3281-3294, 2004. (Pubitemid 39139913)
11. Gewinner C, Hart G, Zachara N, Cole R, Beisenherz-Huss C, Groner B. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem 279: 3563-3572, 2004. (Pubitemid 38140596)
12. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 21: 299-313, 2006. (Pubitemid 43159982)
13. Heidl A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38, Suppl 1: S100-S106, 2001. (Pubitemid 32927622)
14. Holthofer H. Molecular architecture of the glomerular slit diaphragm: lessons learnt for a better understanding of disease pathogenesis. Nephrol Dial Transplant 22: 2124-2128, 2007. (Pubitemid 47244686)
15. Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D. Endothelial cell membranes contain podocalyxin-the major sialoglycoprotein of visceral glomerular epithelial cells. J Cell Biol 102: 484-491, 1986. (Pubitemid 16140809)
16. Kerjaschki D, Sharkey DJ, Farquhar M. Identification and characterization of podocalyxin-the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 98: 1591-1596, 1984. (Pubitemid 14126988)
17. Kerjaschki D, Poczewski H, Dekan G, Horvat R, Balzar E, Kraft N, Atkins RC. Identification of a major sialoprotein in the glycocalyx of human visceral glomerular epithelial cells. J Clin Invest 78: 1142-1149, 1986. (Pubitemid 17181548)
18. Kershaw DB, Wiggins JE, Wharram BL, Wiggins RC. Assignment of the human podocalyxin-like protein (PODXL) gene to 7q32-q33. Genomics 45: 239-240, 1997.
19. Kershaw DB, Beck SG, Wharram BL, Wiggins JE, Goyal M, Thomas Wiggins RC PE. Molecular cloning and characterization of human podocalyxin like protein, orthologous relationship to rabbit PCLP1 and rat podocalyxin. J Biol Chem 272: 15708-15714, 1997.
20. Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B, Tsilibary EC. Glucose-induced changes integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 284: F671-F679, 2003. (Pubitemid 36336973)
21. Koop K, Eikmans M, Baelde HJ, Kawachi H, de Heer E, Paul LC, Bruijn JA. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 14: 2063-2071, 2003. (Pubitemid 36909914)
22. Krishnamurti U, Rondeau E, Sraer JD, Michael A, Tsilibary EC. Alterations in human glomerular epithelial cells interacting withn onenzymatically glycosylated matrix. J Biol Chem 272: 27966-27970, 1997. (Pubitemid 27473602)
23. Nakagama H, Heinrich G, Pelletier J, Housman DE. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cell Biol 15: 1489-1498, 1995.
24. Menke AL, IJpenberg A, Fleming S, Ross A, Medine CN, Patek CE, Spraggon L, Hughes J, Clarke AR, Hastie ND. The wt1-heterozygous mouse; a model to study the development of glomerular sclerosis. J Pathol 200: 667-674, 2003. (Pubitemid 36987318)
25. Pagtalunan ME, Miller PL, Jumping-Eagle M, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997. (Pubitemid 27053474)
26. Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DA. WT1 regulates the expression of the major glomerular podocyte membrane protein podocalyxin. Curr Biol 11: 1805-1809, 2001.
27. Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep 4: 31-36, 2004. (Pubitemid 39359508)
28. Rico M, Mukherjee A, Konieczkowski M, Bruggeman LA, Miller RT, Khan S, Schelling JR, Sedor JR. WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. Am J Physiol Renal Physiol 289: F431-F441, 2005. (Pubitemid 41003673)
29. Roberts SGE. Transcriptional regulation by WT1 in development. Curr Opin Genet Dev 15: 542-547, 2005.
30. Schnabel E, Dekan G, Miettinen A, Farquhar MG. Biogenesis of podocalyxin-the major glomerular sialoglycoprotein - in the newborn rat kidney. Eur J Cell Biol 48: 313-326, 1989. (Pubitemid 19127296)
31. Srichai MB, Konieczkowski M, Padiyar A, Konieczkowski DJ, Mukherjee A, Hayden PS, Kamat S, El-Meanawy MA, Khan S, Mundel P, Lee SB, Bruggeman LA, Schelling JR, Sedor JR. A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. J Biol Chem 279: 14398-14408, 2004. (Pubitemid 38468982)
32. Takeda T, Go WY, Orlo RA, Farquhar MG. Expression of podocalyxin inhibits cell-cell adhesion and modifiesjunctional properties in Madin-Darby canine kidney cells. Mol Biol Cell 11: 3219-3232, 2000. (Pubitemid 32107095)
33. Velasquez MT, Kimmel PL, Michaelis OE. Animal models of spontaneous diabetic kidney disease. FASEB J 11: 2850-2859, 1990. (Pubitemid 120012531)
34. Vlassara H, Brownlee M, Cerami A. Advanced non-enzymatic tissue glycosylation: significance in late diabetic complications. Diabetes Res Clin Pract 7, Suppl 1: S103-S108, 1989. (Pubitemid 19225314)
35. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91: 11704-11708, 1994. (Pubitemid 24356413)
36. Vlassara H. E-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 17: 436-443, 2001.
37. Wagner N, Wagner KD, Xing Y, Scholz H, Schedl A. The major podocyte protein nephrin is transcriptionally activated by the Wilm's tumor suppressor WT1. J Am Soc Nephrol 15: 3044-3051, 2004. (Pubitemid 39578836)
38. Wang W, Lee SB, Palmer R, Ellisen LW, Haber DA. A functional interaction with CBP contributes to transcriptional activation by the Wilms' tumor suppressor WT1. J Biol Chem 276: 16810-16816, 2001. (Pubitemid 37411475)
39. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V, Schmidt AM. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14: 1383-1395, 2003. (Pubitemid 36514678)
40. Yang Y, Jeanpierre C, Dressler GR, Lacoste M, Niaudet P, Gubler MC. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis. Am J Pathol 154: 181-192, 1999. (Pubitemid 29031625)